Related references
Note: Only part of the references are listed.Update on the use of memantine in Alzheimer’s disease
Rob Marum
Neuropsychiatric Disease and Treatment (2010)
Novel Regimens and Delivery Systems in the Pharmacological Treatment of Alzheimer's Disease
Nazem Bassil et al.
CNS DRUGS (2009)
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial
Anton P. Porsteinsson et al.
CURRENT ALZHEIMER RESEARCH (2008)
Memantine for the treatment of Alzheimer's disease
Martin R. Farlow et al.
DRUG SAFETY (2008)
Memantine:: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutarnatergic system -: too little activation is bad, too much is even worse
Chris G. Parsons et al.
NEUROPHARMACOLOGY (2007)
Rationale for transdermal drug administration in Alzheimer disease
Wolfgang Oertel et al.
NEUROLOGY (2007)
Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease
Brian R. Ott et al.
JOURNAL OF NEUROLOGY (2007)
Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease
Roy W. Jones et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2007)
Memantine pharmacotherapy - A naturalistic study using a population pharmacokinetic approach
Johannes Kornhuber et al.
CLINICAL PHARMACOKINETICS (2007)
Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial
Elaine R. Peskind et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2006)
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease
B Reisberg et al.
ARCHIVES OF NEUROLOGY (2006)
Global prevalence of dementia: a Delphi consensus study
CP Ferri et al.
LANCET (2005)
Effects of memantine and donepezil on amyloid β-induced memory impairment in a delayed-matching to position task in rats
K Yamada et al.
BEHAVIOURAL BRAIN RESEARCH (2005)
Depressive disorders in caregivers of dementia patients: A systematic review
P Cuijpers
AGING & MENTAL HEALTH (2005)
The ability of persons with Alzheimer disease (AD) to make a decision about taking an AD treatment
JHT Karlawish et al.
NEUROLOGY (2005)
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil - A randomized controlled trial
PN Tariot et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Glutamate and the glutamate receptor system:: a target for drug action
S Bleich et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2003)
The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence
W Danysz et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2003)
Genomic medicine: Alzheimer's disease and Parkinson's disease
RL Nussbaum et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Memantine in moderate-to-severe Alzheimer's disease
B Reisberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Alzheimer disease: Current concepts and emerging diagnostic and therapeutic strategies
CM Clark et al.
ANNALS OF INTERNAL MEDICINE (2003)
Galantamine - A review of its use in Alzheimer's disease
LJ Scott et al.
DRUGS (2000)
Prevalence of AD among whites - A summary by levels of severity
LX Hy et al.
NEUROLOGY (2000)
Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats
T Kosasa et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Share Paper
